@article{article, title  = {{Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model}},

 url = {{http://eprints.whiterose.ac.uk/100350/ }},

 year = {{2016}},

 month = {{5}},

 author = {{Archer R and Tappenden P and Ren S and Martyn-St James M and Harvey R and Basarir H and Stevens J and Carroll C and Cantrell A and Lobo A and Hoque S}},

 doi = {{10.3310/hta20390}},

 volume = {{20}},

 journal = {{Health Technology Assessment}},

 issue = {{39}},

 pages = {{1-326}},

 note = {{Accessed on 2024/12/22}}}